Data protection Impressum

Pharma

Geneva's Addex Therapeutics has teamed up with Perceptive Advisors to launch spin-off Neurosterix, a new player in neurology-focused drug development.

Addex Therapeutics launches spin-off Neurosterix in Geneva with USD 63 million investment

9 April 2024

Top Stories Western Switzerland

Top Stories from Western Switzerland (February 2024)

27 February 2024

This alliance between Atinary and Takeda is a shining example of how technology and healthcare can come together to create innovative solutions that address pressing challenges in drug development.

Atinary and Takeda forge a strategic alliance to advance healthcare innovation

19 February 2024

The breakthrough comes from the University's Autophagy Laboratory, where Prof. Patricia Boya and her team, in collaboration with the Spanish Margarita Salas Center for Biological Research (CIB-CSIC), have demonstrated the potential of specific drugs to stimulate mitophagy, thereby enhancing the ability of cells to "clean house" even as they age.

University of Fribourg discovers drug to combat age-related neuroinflammation

12 February 2024

GeNeuro‘s mission is to leverage HERV biology to develop safe and effective treatments for the benefit of patients, by neutralizing causal factors encoded by HERVs that represent 8% of human DNA.

GeNeuro secures EUR 5 million to advance post-COVID and neurodegenerative disease treatments

5 February 2024

Founded in 2016 in Argentina, Stämm, now boasting a robust team of over 200 in Buenos Aires and San Francisco, specializes in harnessing nature-inspired, data-driven solutions to revolutionize bioprocessing.

Biomanufacturing innovator Stämm opens its European R&D facility in Monthey

25 January 2024

BioLizard’s move to Lausanne reflects its growing international presence and dedication to serving the Swiss biotech industry.

Bioinformatics specialist BioLizard opens a new office at the Biopôle in Lausanne

24 January 2024

STALICLA has developed the first neurodevelopmental disorder-specific precision medicine platform with an initial application in autism spectrum disorder (ASD).

STALICLA secures USD 17.4 million to propel neuro precision medicine

22 January 2024

For decades, the canton of Valais has cultivated a reputation for excellence in the chemical and pharmaceutical industries, combining innovation with economic growth.

The remarkable chemical-pharmaceutical industry in the canton of Valais

This funding and partnership with the ADDF place GliaPharm at the forefront of developing effective treatments for Alzheimer’s, offering new hope in the fight against this challenging neurodegenerative disease.

GliaPharm receives USD 4.2 million to propel Alzheimer’s treatment development

20 December 2023

1 2 3 4 5 6 7 8 9 10 … 14